Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00401
|
|||||
| Drug Name |
Talinolol
|
|||||
| Synonyms |
(+-)-N-Cyclohexyl-N'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea; (+-)-Talinolol; 1-(3-(3-Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)PHENYL)-3-CYCLOHEXYLUREA; 1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol; 1-(4-Cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane; 38649-73-9; Cordanum; NCGC00164542-01; Racemic talinolol; Talinolol (INN); Talinolol [INN]; Talinololum [INN-Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Gastrointestinal motility disorder [ICD11:DE2Z] | Phase 1 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H33N3O3
|
|||||
| Canonical SMILES |
CC(C)(C)NCC(COC1=CC=C(C=C1)NC(=O)NC2CCCCC2)O
|
|||||
| InChI |
InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)
|
|||||
| InChIKey |
MXFWWQICDIZSOA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 57460-41-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 363.5 | Topological Polar Surface Area | 82.6 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103096738
,103401016
,104343015
,107929351
,117537352
,124580994
,125712702
,126580194
,126725781
,126737449
,127339737
,127339738
,127339739
,131492773
,135027207
,135066580
,135555209
,135653641
,135707467
,135888304
,136895027
,137114987
,142640331
,144205724
,14926104
,162057748
,162118068
,162848586
,164765202
,165745358
,170466514
,170558731
,178101379
,179323274
,184547412
,202554924
,215742084
,226457382
,252091637
,252492541
,26757961
,43125295
,50060575
,50068853
,51091522
,57317059
,77170990
,8192333
,95612779
,98940985
|
|||||
| ChEBI ID |
CHEBI:135533
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [3] | ||
| OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [4] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| References | ||||||
| 1 | ClinicalTrials.gov (NCT01635608) Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water | |||||
| 2 | FDA Drug Development and Drug Interactions | |||||
| 3 | Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res. 2009 Mar;26(3):560-7. | |||||
| 4 | Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010 Jan;332(1):181-9. | |||||
| 5 | Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci. 2007 Oct;96(10):2808-17. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.